IsraelLowyMD
Infectious Disease • Dobbs Ferry, NYAdjunct Assistant Clinical Professor, Medicine - Infectious Diseases, Icahn School of Medicine at Mount Sinai
Are you Dr. Lowy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
42 Appleton Pl
Dobbs Ferry, NY 10522Phone+1 914-674-1146Fax+1 914-674-0967
Summary
- Dr. Israel Lowy, MD is an infectious disease specialist in Dobbs Ferry, New York. He is currently licensed to practice medicine in New York. He is an Adjunct Assistant Clinical Professor at Icahn School of Medicine at Mount Sinai.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Infectious Disease, 1989 - 1990- New York Presbyterian Hospital (Columbia Campus)Fellowship, Infectious Disease, 1987 - 1988
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1984 - 1987
Columbia University Vagelos College of Physicians and SurgeonsClass of 1984
Certifications & Licensure
NY State Medical License 1985 - 2026- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 841 citationsPD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinomaMichael R. Migden, Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild
The New England Journal of Medicine. 2018-06-04 - 312 citationsA Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate CancerEric J. Small, N. Simon Tchekmedyian, Brian I. Rini, Lawrence Fong, Israel Lowy
Clinical Cancer Research. 2007-03-15 - 271 citationsCTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationAsad Bashey, Bridget Medina, Sue Corringham, Mildred Pasek, Ewa Carrier
Blood. 2009-02-12
Press Mentions
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (Cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient PopulationsMay 26th, 2023- Libtayo® (Cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-Line Treatment of Advanced PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)March 29th, 2023
- Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (Cemiplimab) in Multiple Solid Tumor TypesDecember 1st, 2022
- Join now to see all
